ANNOUNCEMENT  |  April 10, 2024

BioPorto Appoints Chief Legal Officer

Gry Louise Husby Larsen was appointed Executive Vice President and Chief Legal Officer (CLO). Read More

PRESS RELEASE  |  April 4, 2024

BioPorto Announces 2023 Annual Results; Releases Annual Report

2023 revenue growth attributed to a 25% increase in NGAL product sales. See the Annual Report for BioPorto’s strategic objectives and detailed action plan for the next 3-5 years. Read More

ANNOUNCEMENT  |  April 2, 2024

Peter Mørch Eriksen Appointed Permanent Group CEO

BioPorto announces Peter Mørch Eriksen as permanent Group CEO after serving as interim CEO since January 2024. Read More

PRESS RELEASE  |  December  7, 2023

BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States

ProNephro AKI (NGAL) is the first Acute Kidney Injury (AKI) biomarker cleared for pediatric use (aged 3 months through 21 years) in the US and is designed to help doctors identify patients at risk of developing or having persistent, moderate-to-severe AKI. Read More

PRESS RELEASE  |  September 11, 2023

Update on NGAL Test Regulatory Pathway

Based on direction from the US Food and Drug Administration (FDA), BioPorto decided to change the regulatory pathway for the Company’s NGAL test from a De Novo to a 510(k). This is not expected to impact the FDA’s ongoing review process.  Read More

PRESS RELEASE  |  November 10, 2022

FDA De Novo Submission with Breakthrough Device Designation

BioPorto submitted an FDA De Novo application with Breakthrough Device Designation for an NGAL test to aid in identifying pediatric patients ≥ 3 months to < 22 years at risk of moderate to severe acute kidney injury.  Read More

PRESS RELEASE  |  June 20, 2022

BioPorto Appoints Dr. Prasad Devarajan as New Senior Medical Director

World-renowned pediatric nephrologist and NGAL expert Dr. Prasad Devarajan will join the BioPorto team effective July 1, 2022. CEO Tony Pare notes that “Dr. Devarajan’s unparalleled reputation, knowledge, and expertise will be a tremendous gain for BioPorto.” Read More